Bexarotene

Active ingredient: Bexarotene

In short: Bexarotene capsules are indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy.

Forms & strengthsCapsules: 75 mg, white, oblong soft gelatin capsules imprinted “A125” with black ink.
LabelAvKARE
Label updatedNov 17, 2025

What is Bexarotene used for?

Bexarotene capsules are indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy.

⚠ Boxed warning (FDA's strongest warning)

Bexarotene is a member of the retinoid class of drugs that is associated with birth defects in humans. Bexarotene also caused birth defects when administered orally to pregnant rats. Bexarotene must not be administered to a pregnant woman.

(8.1)

Bexarotene dosage

The recommended initial dose of bexarotene capsules is 300 mg/m

2/day . Bexarotene capsules should be taken as a single oral daily dose with a meal. For precautions to prevent pregnancy and birth defects in women of child-bearing potential

.

Table 1: Bexarotene Capsules Initial Dose Calculation According to Body Surface Area

Initial Dose Level (300 mg/m

2/day) | Number of 75 mg

Bexarotene Capsules

Body Surface Area (m

2) | Total Daily Dose (mg/day)

0.88 to 1.12 | 300 | 4

1.13 to 1.37 | 375 | 5

1.38 to 1.62 | 450 | 6

1.63 to 1.87 | 525 | 7

1.88 to 2.12 | 600 | 8

2.13 to 2.37 | 675 | 9

2.38 to 2.62 | 750 | 10

Dose Modification Guidelines: The 300 mg/m

2/day dose level of bexarotene capsules may be adjusted to 200 mg/m

2/day then to 100 mg/m

2/day, or temporarily suspended, if necessitated by toxicity. When toxicity is controlled, doses may be carefully readjusted upward. If there is no tumor response after eight weeks of treatment and if the initial dose of 300 mg/m

2/day is well tolerated, the dose may be escalated to 400 mg/m

2/day with careful monitoring.

Duration of Therapy: In clinical trials in CTCL, bexarotene capsules was administered for up to 97 weeks.

Bexarotene capsules should be continued as long as the patient is deriving benefit.

How to take Bexarotene — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Inform the patient or caregiver about the following:

Birth Defects

Advise patients that bexarotene is contraindicated in pregnancy

. Bexarotene is a member of the retinoid class of drugs that is associated with birth defects in humans

.

Advise females of reproductive potential that they must avoid pregnancy while taking bexarotene and for at least one month following discontinuation of therapy.

Advise females of reproductive potential of the importance of monthly pregnancy testing while taking bexarotene.

Advise females of reproductive potential to use effective contraception for one month prior to the initiation of therapy, during therapy, and for at least one month following discontinuation of therapy and that two reliable forms of contraception should be used simultaneously, one of which should be non-hormonal.

Advise females of reproductive potential that bexarotene should be initiated on the second or third day of a normal menstrual period.

Instruct patient to immediately stop taking bexarotene if she becomes pregnant while taking this drug. …

Warnings & precautions

Do not take this medicine if: Bexarotene can cause fetal harm when administered to a pregnant female. Bexarotene is a member of the retinoid class of drugs that is associated with birth defects in humans and is contraindicated in females who are pregnant. Bexarotene was also teratogenic and caused developmental mortality when administered orally to pregnant rats. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be advised of the potential risk to a fetus.

Bexarotene capsules are contraindicated in patients with a known serious hypersensitivity to bexarotene or other components of the product.

Bexarotene induces substantial elevations in lipids in most patients. About 70% of patients with CTCL who received an initial dose of ≥300 mg/m

2/day of bexarotene had fasting triglyceride levels greater than 2.5 times the upper limit of normal. About 55% had values over 800 mg/dL with a median of about 1200 mg/dL in those patients. Cholesterol elevations above 300 mg/dL occurred in approximately 60% and 75% of patients with CTCL who received an initial dose of 300 mg/m

2/day or greater than 300 mg/m

2/day, respectively. Decreases in high density lipoprotein (HDL) cholesterol to less than 25 mg/dL were seen in about 55% and 90% of patients receiving an initial dose of 300 mg/m

2/day or greater than 300 mg/m

2/day, respectively, of bexarotene. Monitor lipid changes and treat abnormalities during therapy. The effects on triglycerides, HDL cholesterol, and total cholesterol were reversible with cessation of therapy, and could generally be mitigated by dose reduction and/or concomitant antilipemic therapy. …

Bexarotene side effects

The following serious adverse reactions are discussed in greater detail in other sections of the prescribing information:

Hyperlipidemia

Pancreatitis

Hepatotoxicity, cholestasis, and hepatic failure

Hypothyroidism

Neutropenia

Cataracts

Vitamin A Supplementation Hazard

Hypoglycemia Risk in Patients with Diabetes Mellitus

Photosensitivity

Laboratory Tests

Drug/Laboratory Test Interactions

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of bexarotene has been evaluated in two clinical trials of 152 patients with CTCL who received bexarotene for up to 97 weeks and in 352 patients in other trials. The mean duration of therapy for the 152 patients with CTCL was 166 days. The most common adverse events reported with an incidence of at least 10% in patients with CTCL treated at an initial dose of 300 mg/m

2/day of bexarotene are shown in Table 2. The events at least possibly related to treatment are lipid abnormalities (elevated triglycerides, elevated total and LDL cholesterol and decreased HDL cholesterol), hypothyroidism, headache, asthenia, rash, leukopenia, anemia, nausea, infection, peripheral edema, abdominal pain, and dry skin. Most adverse events occurred at a greater incidence in patients treated at starting doses of greater than 300 mg/m

2/day . …

Drug interactions

Effect of Other Drugs on Bexarotene

Gemfibrozil: Concomitant administration of bexarotene and gemfibrozil resulted in increases in plasma concentrations of bexarotene. Concomitant administration of gemfibrozil with bexarotene is not recommended.

Effect of Bexarotene

on Other Drugs

Bexarotene may be an inducer for the CYP3A4 enzymes, and may reduce plasma concentrations of other substrates metabolized by CYP3A4. Drug products which may be affected include oral or other systemic hormonal contraceptives. Thus, if treatment with bexarotene is intended for a female with reproductive potential, it is strongly recommended that a non-hormonal contraception be considered

.

Laboratory Test Interference

CA125 assay values in patients with ovarian cancer may be increased by bexarotene therapy.

About this medicine

Bexarotene capsules contain bexarotene, a member of a subclass of retinoids that selectively activate retinoid X receptors (RXRs). These retinoid receptors have biologic activity distinct from that of retinoic acid receptors (RARs).

The chemical name of bexarotene is 4-[1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl) ethenyl] benzoic acid, and the structural formula is as follows:

Bexarotene is an off-white to white powder with a molecular weight of 348.48 and a molecular formula of C

24H

28O

2. It is insoluble in water and slightly soluble in vegetable oils and ethanol, USP.

Each bexarotene capsule contains 75 mg of bexarotene for oral administration. It also contains the following inactive ingredients: butylated hydroxyanisole, polyethylene glycol 400, polysorbate 20 and povidone. The capsule shell contains gelatin, glycerin, purified water, sorbitol sorbitan solution, and titanium dioxide. The imprinting ink contains ammonium hydroxide, iron oxide black, isopropyl alcohol, n-butyl alcohol, propylene glycol and shellac glaze. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID f9514265-6e2c-9030-e053-6394a90aa04b. Read the full official label on DailyMed.

Related medicines

Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate